Navigation Links
Lexicon Announces Top-Line Phase 2a Data for LX2931 in Patients with Rheumatoid Arthritis
Date:12/14/2010

THE WOODLANDS, Texas, Dec. 14, 2010 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced top-line results from a recently completed Phase 2a study of LX2931 in patients with rheumatoid arthritis (RA).  LX2931 is an orally-delivered, small molecule drug candidate that inhibits sphingosine-1-phosphate (S1P) lyase, an enzyme important for modulating the immune system by controlling S1P levels in lymphoid tissues. The trial was the first test of this new anti-inflammatory mechanism of action in patients and was designed to obtain safety and tolerability information and signals of efficacy.  

Results from the 12-week, randomized, double-blind, placebo-controlled study in 208 patients with RA demonstrated that all three doses tested, 70 mg, 110 mg, and 150 mg given once per day, were well tolerated over the 12-week treatment period.  Taken together, the data also suggested that patients treated with 150 mg once daily of LX2931 showed an improvement in the primary efficacy endpoint, the percentage of patients achieving an American College of Rheumatology 20 (ACR20) response at week 12 (60% versus 49% for placebo).  Patients treated with 70 mg or 110 mg once daily did not indicate improvement in the ACR20 at week 12 (44% and 41% response rates, respectively) relative to placebo. Adverse events for all three LX2931 dose groups were predominantly mild-to-moderate, with frequencies similar to the placebo group.

"We believe the preliminary signal of efficacy and the favorable safety profile observed in this trial supports further study
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
2. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
3. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
4. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
5. Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
6. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
7. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
8. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
9. Lexicon Announces Pricing of Common Stock in Public Offering
10. Lexicon Announces Completion of Public Offering of Common Stock
11. Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Sept. 2, 2014 Astellas has appointed James ... (IP) in the Americas. Kellerman will report directly to ... counsel at Astellas. In his new role, Kellerman will ... the business and manage the region,s intellectual property matters, ... "I am very pleased to welcome Jim to Astellas. ...
(Date:9/2/2014)... Sept. 2, 2014  Numotion is pleased to announce the ... of Directors. Mark is a 30-year retired ... positions across the organization and was a GE Company Officer ... Mark spent many years running business units within GE Healthcare, ... Healthcare Americas. "We are delighted to welcome ...
(Date:9/2/2014)... Texas , Sept. 2, 2014  On July ... notice to Congress that it is moving forward to ... down the minutes until laboratories throughout the U.S. will ... Although some medical laboratories may subscribe to ... the FDA to put guidelines in place, it,s widely ...
Breaking Medicine Technology:Leading Intellectual Property Counsel, James Kellerman, Joins Astellas as Vice President 2FDA Tells Congress It Intends to Regulate LDTs! Web Conference to Provide Straight Talk on Essential Steps Clinical Laboratories and Pathology Groups Will Need to Take to Comply 2FDA Tells Congress It Intends to Regulate LDTs! Web Conference to Provide Straight Talk on Essential Steps Clinical Laboratories and Pathology Groups Will Need to Take to Comply 3
... Today, Siemens (NYSE: SI ) announces the appointment ... Officer (CMIO), of the Health Services (HS) Business Unit. One ... Health Information Exchange (IHIE), Marc recently served as the President ... Siemens, Marc will be responsible for clinical informatics activities and ...
... Minn., Feb. 21, 2011 Acuo Technologies®, a ... the medical imaging industry for archiving, collaboration and ... of the latest release of its market leading ... significant enterprise capabilities including cloud-enablement, workflow services, and ...
Cached Medicine Technology:Siemens Appoints Overhage as New Chief Medical Informatics Officer 2Acuo Technologies Announces New Enterprise Capabilities with Latest Software Release 2
(Date:9/2/2014)... 03, 2014 Recently, Top 10 ... companies and announced that JustHost ( http://www.justhost.com/track/seohosts ) ... webmasters. , “The hosting suppliers we recommend are ... competitors on hosting features, uptime and server speed ... Best SEO Hosting says. “We believe that BlueHost ...
(Date:9/2/2014)... The exciting information sessions and AMTC ... Carey Lewis and Bob Wiley. The team of ... have the desire to illuminate entertainment with the light ... be invited to join the Bridge Training Program ... Saturday, Sept. 6, Charlotte Convention Center, 501 South College ...
(Date:9/2/2014)... Washington, DC (PRWEB) September 02, 2014 TCG, ... named by Inc. 5000 as one of the fastest-growing companies ... the eighth time total. TCG was previously recognized in 2013, ... 2001. , TCG’s revenue has grown 86% from 2010 to ... of the fastest growing businesses in America - up 635 ...
(Date:9/2/2014)... 02, 2014 Friendship Village of ... “This creates a contemporary marketing presence and ... its parent organization, Friendship Senior Options,” said Stephen ... Options. “By changing the logo, we are making ... to seniors and their families.” , Friendship Village ...
(Date:9/2/2014)... September 02, 2014 Cloud Medical Doctor ... “Cloud Based” Medical Practice Business Operations solutions and Billing ... Digital Cyber Security solutions for all industries announced today ... the trading floor of the CME in Chicago by ... stated that we are very proud of the recognition ...
Breaking Medicine News(10 mins):Health News:Actors, Models and Talent for Christ Auditions Are Set for Charlotte and Omaha on Saturday, September 6, 2014 2Health News:TCG One of the Fastest-Growing Companies in America – for the Eighth Time! 2Health News:Friendship Village of Schaumburg In Illinois Announces New Logo 2Health News:Cloud Medical Doctor Software Corporation's CEO Interviewed by the Price Futures Group 2Health News:Cloud Medical Doctor Software Corporation's CEO Interviewed by the Price Futures Group 3
... the recent economic downturn, natural health degree ... still experiencing a wellness boom, as holistic ... the Internet,s top natural health career site ... training, chiropractic, nutrition, Reiki and reflexology career ...
... Upsher-Smith announces the launch of www.prenexa.com , a web site ... with more plant-based DHA (docosahexaenoic acid) than any other prenatal vitamin. ... ... Upsher-Smith announces the launch of prenexa.com, a web site devoted to ...
... from the Dutch Health Insurance System model, according to an ... of the Journal of Health Politics, Policy and Law ... at The University of Texas School of Public Health at ... coverage in the Netherlands and its possible lessons for the ...
... prevention and treatment for people living with HIV/AIDS. , ... ... annual World AIDS Day , global health activists gathered for ... today that nearly 6,000 people from 163 countries signed a petition ...
... SAN FRANCISCO, Dec. 8 Quantros, a leading ... healthcare industry, today,announced that the Agency for Healthcare ... Quantros Patient Safety Center as a Patient Safety,Organization ... . The Quantros Patient Safety Center,is a new ...
... iron from the heart in beta-thalassemia patients with mild to severe ... a subgroup analysis of 341 patients with myelodysplastic syndromes (MDS), Exjade ... -These results are part of the largest prospective trial ... transfusion-dependent anemias , , EAST HANOVER, ...
Cached Medicine News:Health News:Natural Healers Researches Natural Health Careers to Make the Prospective Holistic Health Students' Job Easier 2Health News:Natural Healers Researches Natural Health Careers to Make the Prospective Holistic Health Students' Job Easier 3Health News:Upsher-Smith Laboratories Launches Prenexa.com to Support Prenatal Nutrition and Health 2Health News:Upsher-Smith Laboratories Launches Prenexa.com to Support Prenatal Nutrition and Health 3Health News:UT public health policy expert says US can learn from Dutch universal health-care coverage 2Health News:Thousands Sign Petition for Action on HIV/AIDS and Malaria 2Health News:Thousands Sign Petition for Action on HIV/AIDS and Malaria 3Health News:Thousands Sign Petition for Action on HIV/AIDS and Malaria 4Health News:Quantros Patient Safety Center Receives Certification as a Patient Safety Organization (PSO) 2Health News:Exjade(R) Benefits Chronically Transfused Patients by Significantly Reducing Toxic Iron That Can Damage Key Organs, According to Landmark Trial 2Health News:Exjade(R) Benefits Chronically Transfused Patients by Significantly Reducing Toxic Iron That Can Damage Key Organs, According to Landmark Trial 3Health News:Exjade(R) Benefits Chronically Transfused Patients by Significantly Reducing Toxic Iron That Can Damage Key Organs, According to Landmark Trial 4Health News:Exjade(R) Benefits Chronically Transfused Patients by Significantly Reducing Toxic Iron That Can Damage Key Organs, According to Landmark Trial 5Health News:Exjade(R) Benefits Chronically Transfused Patients by Significantly Reducing Toxic Iron That Can Damage Key Organs, According to Landmark Trial 6Health News:Exjade(R) Benefits Chronically Transfused Patients by Significantly Reducing Toxic Iron That Can Damage Key Organs, According to Landmark Trial 7Health News:Exjade(R) Benefits Chronically Transfused Patients by Significantly Reducing Toxic Iron That Can Damage Key Organs, According to Landmark Trial 8Health News:Exjade(R) Benefits Chronically Transfused Patients by Significantly Reducing Toxic Iron That Can Damage Key Organs, According to Landmark Trial 9
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: